Abstract
Over the past few decades significant advances have been made in the development of nanopharmaceuticals (including phospholipid and polymer-based therapeutics) against cancer. There is still, however, room for improvement. Today, many researchers are focusing on the development of innovative approaches to selectively deliver drugs to solid tumors, while minimizing insult to healthy tissues. Unfortunately, the majority of these efforts are confronted by physiological barriers that reduce the clinical dose required to effectively manage the disease state. In an effort to develop promising nanopharmaceutical products of the future, we review the most important problems facing drug delivery experts today. We discuss here, the physiological role of solid tumors in delivery and transport of nanopharmaceutical products. The nature of tumors in terms of their unique anatomical structure and functions is also discussed. Finally, an overview of ways to overcome physiological barrier functions and exploit tumor pathogenesis for therapeutic gain is provided.
Keywords: Tumor vasculature, interstitial transport, vascular permeability, interstitial fluid pressure
Anti-Cancer Agents in Medicinal Chemistry
Title: Tumor Physiology and Delivery of Nanopharmaceuticals
Volume: 6 Issue: 6
Author(s): Robert B. Campbell
Affiliation:
Keywords: Tumor vasculature, interstitial transport, vascular permeability, interstitial fluid pressure
Abstract: Over the past few decades significant advances have been made in the development of nanopharmaceuticals (including phospholipid and polymer-based therapeutics) against cancer. There is still, however, room for improvement. Today, many researchers are focusing on the development of innovative approaches to selectively deliver drugs to solid tumors, while minimizing insult to healthy tissues. Unfortunately, the majority of these efforts are confronted by physiological barriers that reduce the clinical dose required to effectively manage the disease state. In an effort to develop promising nanopharmaceutical products of the future, we review the most important problems facing drug delivery experts today. We discuss here, the physiological role of solid tumors in delivery and transport of nanopharmaceutical products. The nature of tumors in terms of their unique anatomical structure and functions is also discussed. Finally, an overview of ways to overcome physiological barrier functions and exploit tumor pathogenesis for therapeutic gain is provided.
Export Options
About this article
Cite this article as:
Campbell B. Robert, Tumor Physiology and Delivery of Nanopharmaceuticals, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (6) . https://dx.doi.org/10.2174/187152006778699077
DOI https://dx.doi.org/10.2174/187152006778699077 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry The Prodigiosins: A New Family of Anticancer Drugs
Current Cancer Drug Targets A Qualitative and Quantitative Study of the Innervation of the Human Non Pregnant Uterus
Current Protein & Peptide Science Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Recent Patents Involving Virus Nucleotide Sequences; Host Defense, RNA Silencing and Expression Vector Strategies
Recent Patents on DNA & Gene Sequences Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy
Mini-Reviews in Medicinal Chemistry Recent Developments of Nanoparticles in the Treatment of Photodynamic Therapy for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway
Current Cancer Drug Targets Utilization of Ribozymes as Antiviral Agents
Letters in Drug Design & Discovery The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology Editorial (Thematic Issue: Clonal Heterogeneity and Diversification in B-cell Disorders)
Current Cancer Therapy Reviews Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Recent Patents on Rho Signaling Pathway as Therapeutic Target for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Identification of a Novel Human Peroxisomal 2,4-Dienoyl-CoA Reductase Related Protein Using the M13 Phage Protein VI Phage Display Technology
Combinatorial Chemistry & High Throughput Screening Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Oxidative Stress Modulation and Radiosensitizing Effect of Quinoxaline-1,4-Dioxides Derivatives
Anti-Cancer Agents in Medicinal Chemistry Meaning Centered Psychotherapy: The State of the Art
Current Psychiatry Reviews An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design